Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer

BACKGROUND: The solute carrier family 7 (SLC7) can be categorically divided into two subfamilies, the L-type amino acid transporters (LATs) including SLC7A5-13, and SLC7A15, and the cationic amino acid transporters (CATs) including SLC7A1-4 and SLC7A14. Members of the CAT family transport predominantly cationic amino acids by facilitating diffusion with intracellular substrates. LAT1 (also known as SLC7A5), is defined as a heteromeric amino acid transporter (HAT) interacting with the glycoprotein CD98 (SLC3A2) through a conserved disulfide to uptake not only large neutral amino acids, but also several pharmaceutical drugs to cells

METHODS: In this review, we provide an overview of the interaction of the structure-function of LAT1 and its essential role in cancer, specifically, its role at the blood-brain barrier (BBB) to facilitate the transport of thyroid hormones, pharmaceuticals (e.g., I-DOPA, gabapentin), and metabolites into the brain

RESULTS: LAT1 expression increases as cancers progress, leading to higher expression levels in highgrade tumors and metastases. In addition, LAT1 plays a crucial role in cancer-associated reprogrammed metabolic networks by supplying tumor cells with essential amino acids

CONCLUSION: The increasing understanding of the role of LAT1 in cancer has led to an increase in interest surrounding its potential as a drug target for cancer treatment

Year of Publication: 2019
Contained in: Current cancer drug targets Vol. 19, No. 11 (2019), p. 863-876
All journal articles: Search for all articles in this journal
Language: English
Contributors: Lu, Xinjie | Author
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Journal Article
LAT1
cancer
heteromeric amino acid transporter (HAT)
inhibitor
structure
transporter.
ISSN: 1873-5576
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 06.01.2020
published: Print
Citation Status In-Data-Review
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.2174/1568009619666190802135714
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03119nma a2200541 c 4500
001 NLM300526717
003 DE-601
005 20200220195918.0
007 cr uuu---uuuuu
008 190808s2019 000 0 eng d
024 7 |a 10.2174/1568009619666190802135714  |2 doi 
028 5 2 |a pubmed20n1040.xml 
035 |a (DE-599)NLM31376820 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Lu, Xinjie 
245 1 4 |a The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Revised 06.01.2020 
500 |a published: Print 
500 |a Citation Status In-Data-Review 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. 
520 |a BACKGROUND: The solute carrier family 7 (SLC7) can be categorically divided into two subfamilies, the L-type amino acid transporters (LATs) including SLC7A5-13, and SLC7A15, and the cationic amino acid transporters (CATs) including SLC7A1-4 and SLC7A14. Members of the CAT family transport predominantly cationic amino acids by facilitating diffusion with intracellular substrates. LAT1 (also known as SLC7A5), is defined as a heteromeric amino acid transporter (HAT) interacting with the glycoprotein CD98 (SLC3A2) through a conserved disulfide to uptake not only large neutral amino acids, but also several pharmaceutical drugs to cells 
520 |a METHODS: In this review, we provide an overview of the interaction of the structure-function of LAT1 and its essential role in cancer, specifically, its role at the blood-brain barrier (BBB) to facilitate the transport of thyroid hormones, pharmaceuticals (e.g., I-DOPA, gabapentin), and metabolites into the brain 
520 |a RESULTS: LAT1 expression increases as cancers progress, leading to higher expression levels in highgrade tumors and metastases. In addition, LAT1 plays a crucial role in cancer-associated reprogrammed metabolic networks by supplying tumor cells with essential amino acids 
520 |a CONCLUSION: The increasing understanding of the role of LAT1 in cancer has led to an increase in interest surrounding its potential as a drug target for cancer treatment 
611 2 7 |a Journal Article  |2 gnd 
655 7 |a LAT1  |2 gnd 
655 7 |a cancer  |2 gnd 
655 7 |a heteromeric amino acid transporter (HAT)  |2 gnd 
655 7 |a inhibitor  |2 gnd 
655 7 |a structure  |2 gnd 
655 7 |a transporter.  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a LAT1 
689 1 1 |a cancer 
689 1 2 |a heteromeric amino acid transporter (HAT) 
689 1 3 |a inhibitor 
689 1 4 |a structure 
689 1 5 |a transporter. 
689 1 |5 DE-601 
773 0 8 |i in  |t Current cancer drug targets  |g Vol. 19, No. 11 (2019), p. 863-876  |q 19:11<863-876  |w (DE-601)NLM120493810  |x 1873-5576 
856 4 1 |u http://dx.doi.org/10.2174/1568009619666190802135714  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 19  |j 2019  |e 11  |h 863-876